NVP-BEZ235 |
DACTOLISIB |
BEZ-235 |
NVP-BEZ235-NX |
BEZ235 |
Notes | catalytic, dual PI3K/mTOR inhibitor |
Drug Class | Kinase Inhibitors |
Pharmaceutical Developer | Novartis |
Source Reported Drug Name(s) | BEZ235 |
Drug Class | PI3K/mTOR dual Inhibitor |
n/a |
n/a |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
Reported Cancer Type | Melanoma |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | PI3-kinase class I inhibitor |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | PI3-kinase class I inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Reported Cancer Type | Melanoma |
Mechanism of Interaction | Serine/threonine-protein kinase mTOR inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | PI3-kinase class I inhibitor |
Direct Interaction | yes |
Dactolisib | PubChem Drug Name |
11977753 | PubChem Drug ID |
BEZ235 | Drug Trade Name |
Drug Class | PI3K/mTOR dual Inhibitor |
Source Reported Drug Name(s) | BEZ235 |
Pharmaceutical Developer | Novartis |
BEZ235 | Development Name |
Drug Class | Kinase Inhibitors |
Notes | catalytic, dual PI3K/mTOR inhibitor |
CHEMBL1879463 | ChEMBL Drug ID |
BEZ235 | Primary Drug Name |
BEZ235 | Drug Synonym |
D0VG0D | TTD Drug ID |